Board

Chairman - Andrew Allars

Andy is CEO of Wyvern Asset Management which invests in spin-out opportunities from the Universities of Bristol and Southampton. He is also Managing Partner of venture consultancy, Anauel LLP. Andy entered the venture capital industry in 1990 and was until 2004, Head of Life Sciences at Prelude Ventures Limited, a specialist venture capital investor in early stage technology companies. During his time at Prelude he was closely involved in several successful start up bioscience companies including Acambis plc (now part of Sanofi), Quadrant Healthcare plc (now part of Vectura plc), Danby Medical Limited (now part of Baxter Inc) and Oxford Biomedica plc

Chief Scientific Officer and Director - Anthony Hollander

Anthony is a World leading scientist who pioneered the first tissue engineered trachea transplant to critical acclaim before founding Azellon. In 2010, the "Times" newspaper ranking of Britain's 100 most important scientists included him at number 39 on the list. He is President-elect of the International Cartilage Repair Society. Anthony is responsible for all scientific activities in the company and is also Head of the School of Cell Biology and Molecular Medicine at the University of Bristol.

HOME ο THE COMPANY ο TECHNOLOGY ο PARTNERING AND LICENSING ο INVESTORS ο PRESS ο CONTACT ο SITE MAP ο PRINT THIS PAGE ο LOG-IN

Registered Address: The Walbrook Building, 25 Walbrook, London EC4N 8AF | Company reg. no. 6447 651

© 2018 Azellon